Editas Medicine Stock News

Shares of Editas Medicine, Inc. (NASDAQ:EDIT) gapped up before the market opened on Monday . The stock had previously closed at $29.01, but opened at $30.50. Editas Medicine shares last traded at $30.55, with a volume of 12,204 shares trading hands. Several equities analysts recently issued reports on the stock. Oppenheimer raised shares of Editas []

One would have hoped that EDIT chose a more aggressive portfolio that matches its cutting-edge tech. Instead, it decided to walk a more trodden path.

Westside Investment Management Inc. lessened its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 37.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,150 shares of the company’s stock after selling 1,300 shares during the quarter. Westside Investment Management Inc.’s holdings in Editas Medicine were worth $8,062,000 as […]

Protara Therapeutics (NASDAQ:TARA) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership. Profitability This table compares Protara Therapeutics and Editas Medicine’s net margins, return on equity and return […]

Check out these pharmaceutical players on the move now.

Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR). The post NES, WTTR: The Deal That Has Penny Stock Nuverra Environment

The stock price of Editas Medicine Inc (NASDAQ: EDIT) increased by over 9% pre-market today. This is why it happened.

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibody significantly reduce tumor burden iNKs with double knock-out of CISH and TGFR2 substantially reduce tumor

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 12.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 4,262,572 shares of the companys stock after selling 613,847 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned 0.06% of Editas Medicine worth $175,106,000 at the end of the []

Total Clarity Wealth Management Inc. acquired a new position in Editas Medicine, Inc. (NASDAQ:EDIT) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,800 shares of the companys stock, valued at approximately $115,000. A number of other large investors []

The heavy selling pressure might have exhausted for Editas (EDIT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in

After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision

Wall Street analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to post ($0.82) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Editas Medicines earnings, with estimates ranging from ($1.16) to ($0.65). Editas Medicine reported earnings per share of ($1.00) in the same quarter last year, which []

Editas (EDIT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea

Exchange Traded Concepts LLC lowered its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 72.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 26,302 shares of the companys stock after selling 69,599 shares during the quarter. Exchange Traded Concepts LLCs holdings in Editas Medicine were worth $1,080,000 []